Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Therapeutic sunscreen?

This article was originally published in The Tan Sheet

Executive Summary

A team of researchers have developed two "commercially attractive prototypes" of a sunscreen ingredient capable of repairing skin-damage caused by UV light and helping prevent skin cancer, according to a Sept. 7 release from the University of Bath. The novel ingredient reduces pain and inflammation by "moping up" iron released when skin burns, according to the release. The ingredient can also prevent buildup of free radicals generated by sunlight, which can lead to skin cancer development, and increase the efficacy and durability of sunscreen, the University of Bath adds. The prototypes, which contain "caged" iron binding sites which release chelators in response to high doses of UV light, are currently in lab trials and human trials are expected in the next two to three years, according to the release. The light-responsive feature prevents the cell-toxicity associated with chelators, researcher Charareh Pourzand, University of Bath explains. The prototypes are based on research published in the May 2006 Journal of Investigative Dermatology...

You may also be interested in...

Coronavirus Update: Novartis Targets COVID-19 Cytokine Storm With Jakavi

Jakavi joins the likes of Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients

As China Rushes Medical Supplies To World, Quality Issues Resurface

As China is poised to supply globally medical products to fight coronavirus, a battle to banish its image of poor product quality is on.

UK Regulator Puts Energies Into COVID-19 While Other Services May Take Longer

With finite resources, the UK’s regulatory agency responsible for health care products is rapidly addressing COVID-19 medtech issues. But shifting its focus will cause delays elsewhere.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts